Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3916937 | 1.00 | NPC1 (0.68) | NPC1RAB9ACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL15033571 | 0.84 | NPC1 (0.70) | NPC1RAB9ACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL11197051 | 0.82 | ALDH1A1 (0.76) | NPC1RAB9ACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4310718 | 0.82 | KDM4E (0.68) | RAB9ACYP2C9CYP2C19ALDH1A1HTT | |
| SCHEMBL20237020 | 0.82 | SMN1; SMN2 (0.68) | NPC1RAB9ACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL1407210 | 0.82 | NPC1 (0.68) | NPC1RAB9ACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL12693 | 0.82 | ALDH1A1 (0.76) | NPC1RAB9ACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5433044 | 0.82 | LMNA (0.57) | RAB9ACYP2C9CYP2C19ALDH1A1HTT | |
| SCHEMBL12694399 | 0.82 | NPC1 (0.68) | NPC1RAB9ACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4395856 | 0.82 | POLB (0.66) | RAB9ACYP2C9CYP2C19ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153647-B2 | Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2012-04-10 | — | — | US | disclosed |
| CN-101466694-B | Aryl-and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their use in therapeutics | SANOFI AVENTIS | 2012-03-21 | — | — | CN | disclosed |
| EP-2035401-B1 | ARYL- AND HETEROARYL-ETHYL-ACYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2011-02-23 | — | — | EP | disclosed |
| US-20090203696-A1 | Aryl- and Heteroaryl-Ethyl-Acylguanidine Derivatives, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| CN-101466694-A | Aryl-and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their use in therapeutics | SANOFI AVENTIS (FR) | 2009-06-24 | — | — | CN | disclosed |
| EP-2035401-A2 | ARYL- AND HETEROARYL-ETHYL-ACYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | Sanofi-Aventis (FR) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007144769-A2 | ARYL- AND HETEROARYL-ETHYL-ACYLGUANIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203696-A1 | Aryl- and Heteroaryl-Ethyl-Acylguanidine Derivatives, Their Preparation and Their Application in Therapeutics | RAB9A, UGT1A9, CD59 | NPC1 517/4885RAB9A 1/4885CYP2C9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.